Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) (USD $)
In Thousands, except Share data
Series A Convertible Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated other comprehensive loss
Accumulated Deficit
Total
Beginning Balance, Amount at Dec. 31, 2013 $ 10,108       $ 3,502    $ (12,335) $ (8,833)
Beginning Balance, Shares at Dec. 31, 2013 7,046 279           
Conversion of Series A Convertible Preferred Stock (7,046) 721           
Conversion of Series A Convertible Preferred Stock, Amount (10,108) 1    10,107        
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Shares       115,907        
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Amount       116 (1,596)        
Exercise of common stock options, Shares       478        
Exercise of common stock options, Amount          57        
Stock-based compensation          20       25
Issuance of common stock and warrants in January 2014, Shares       5,500        
Issuance of common stock and warrants in January 2014, Amount       6 (6)        
Unrealized gain on marketable securities             1,827    2,235
Net income (loss)                4,357 1,808
Ending Balance, Amount at Sep. 30, 2014    $ 1 $ 123 $ 12,146 $ 2,235 $ (10,527) $ 3,978
Ending Balance, Shares at Sep. 30, 2014    1,000 122,494